EMBL-EBI is a highly collaborative organisation and we place a high value on our work with other leading research institutes and industry partners. Our data services are run jointly with partners throughout the world, and our research groups play a key role in many projects of global significance. We are a pivotal partner in several of Europe’s emerging research infrastructures, and coordinate the preparatory phase of ELIXIR, the emerging infrastructure for biological information in Europe.
Each of our research groups is highly collaborative and works with our partners worldwide on a range of projects. In addition to publishing in prestigious peer reviewed journals, our research groups also produce innovative, novel software databases and tools which are freely available to our users.
Our many research collaborations are too numerous to list here but we invite you to explore these through the individual research group pages.
EMBL-EBI adopts a collaborative approach to its database service provision, serving as the European node for globally coordinated data collection and dissemination projects. Our core databases are produced in collaboration with other world leaders, including the NCBI (US), the National Institute of Genetics (Japan), the SIB Swiss Institute of Bioinformatics (Switzerland), the Wellcome Trust Sanger Institute (UK) and Cold Spring Harbor Laboratory (US). Our collaborations enable us to offer the world’s most comprehensive collection of molecular databases.
EMBL-EBI is a pivotal partner in ELIXIR, the emerging pan-European infrastructure for biological information. The purpose of ELIXIR is to support life science research and its translation to medicine and the environment, the bio-industries and society.
On behalf of ELIXIR, EMBL-EBI coordinates BioMedBridges, which develops technical bridges for interoperability between data and services in the ESFRI biomedical sciences research infrastructures. ELIXIR and BioMedBridges are collaborative projects undertaken with our partners in the European Member States.
DDMoRe, the Drug Disease Model Resources consortium, is developing a public drug and disease model library.
EHR4CR is designing a scalable and cost-effective approach to interoperability between electronic health record systems and clinical research.
EMBRC is working to ensure that marine researchers have access to marine species, biobanks, dedicated ‘omics’ platforms, structural biology facilities and microscopy.
EU Openscreen - the European Infrastructure of Open Screening Platforms for Chemical Biology - integrates high-throughput screening platforms, chemical libraries, chemical resources for hit discovery and optimisation, bio- and cheminformatics support, and a database containing screening results, assay protocols, and chemical information.
Infrafrontier is a major initiative to ensure that the biomedical research community has the tools needed to unravel the role of gene function in human disease.
The 1000 Genomes Project- sequencing the genomes of 2500 people throughout the world in order to build a comprehensive resource on human genetic variation.
eTOX - developing innovative in silico strategies and novel software tools to better predict the toxicological profiles of small molecules in early stages of the drug development pipeline.
HipSci - creating a UK national stem cell cell resource and using it to discover how genomic variation impacts cellular phenotype.
The International Mouse Phenotyping Consortium - developing an encyclopaedia of mammalian gene function.
The EMBL-EBI Industry Programme is a forum for interaction between EMBL-EBI and the industrial life-science research sector.
Members include leading pharmaceutical and agribusiness companies who engage with EMBL-EBI in the development of services and standards, and collaborate on pre-competitive projects.
In 2012 the EMBL Director General Iain Mattaj, together with Mike Stratton, Director of the Wellcome Trust Sanger Institute, and Janet Thornton, Director of EMBL-EBI, signed an agreement formalising the cooperation between the institutes. Sanger and EMBL-EBI have shared the Wellcome Trust Genome Campus in Hinxton since 1996 - a proximity that fosters close collaborations and contributes to an international and vibrant working environment. Formalising these long-standing links heralds an exciting future of ongoing scientific collaboration and cooperation in areas such as services, research, training, technology, public engagement and campus activities.